TSX: MFI
www.mapleleaffoods.com
Meat Protein posts sequential Adjusted EBITDA
Margin improvement to 11.4% in the quarter
Plant Protein progressing toward Adjusted EBITDA
target of neutral by end of 2023
MISSISSAUGA, ON, Nov. 2, 2023
/PRNewswire/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or
the "Company") (TSX: MFI) today reported its financial results for
the third quarter ended September 30, 2023.
"For the third consecutive quarter, we delivered sequential
improvement in Adjusted EBITDA margin in our Meat Protein business,
while also making meaningful strides toward achieving our Adjusted
EBITDA neutral goal in our Plant Protein business," said
Curtis Frank, President and CEO of
Maple Leaf Foods. "Delivering 11.4% Adjusted EBITDA margin in
our Meat Protein business in the face of improving, but still
challenging market conditions, demonstrates clear momentum in our
core business."
"Looking ahead, we will continue to build on this momentum by
remaining firmly focused on delivering the benefits from our
capital investments, executing our strategic Blueprint, and
deleveraging our balance sheet," continued Mr. Frank. "We have
already started to see some benefits in our results from our two
largest capital projects, London Poultry and the Bacon Centre of
Excellence, and we expect to exit the year with an annualized run
rate of about $130 million in
Adjusted EBITDA contribution from these projects. At the same
time, we are forecasting lower capital spend as we wrap up these
large-scale organic projects."
"Based on the strength of our assets, the power of our leading
brands and product innovation, and the passion of our people, we
are confident that we are poised to achieve our goal of 14-16%
Adjusted EBITDA margin in our Meat Protein business when markets
normalize," concluded Mr. Frank.
Third Quarter 2023 Highlights
- Total Company sales grew 1.1% to $1,245.0 million, with an Adjusted Earnings
Before Interest, Taxes, Depreciation and Amortization
("EBITDA")(i) Margin of 10.4%.
- Meat Protein Group sales grew to $1,211.0 million, an increase of 1.4% year over
year. Adjusted EBITDA was $138.4
million, and Adjusted EBITDA Margin was 11.4%, an
improvement of 290 basis points compared to the same period last
year, and 210 basis points from the second quarter of 2023.
- Plant Protein Group sales were $36.4
million. Plant Protein Group Adjusted EBITDA improved by
61.3% year over year to a loss of $9.4
million, en route to an Adjusted EBITDA target of neutral by
the end of 2023.
- Capital expenditures were $50.5
million.
- The London Poultry facility transition is progressing on
schedule. Three legacy facilities have fully transitioned their
production volumes, and the transition from the fourth facility
will begin shortly. The Company expects London Poultry to be fully
ramped up by the end of 2023.
Outlook
- Meat Protein: Expect mid-single digit sales growth in
2023, and Adjusted EBITDA Margin expansion to achieve a target
range of 14% - 16% when markets normalize.
- Plant Protein: On track to deliver Adjusted
EBITDA neutral by the end of 2023.
- Capital expenditure: For 2023 is expected to be
roughly $200 million, down from prior
guidance of less than $250 million.
Approximately half of the spend will be attributable to Maintenance
Capital(i) and the balance attributable to Growth
Capital(i).
(i)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Financial Highlights
|
As at or for
the
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
September 30,
|
|
Nine months ended
September 30,
|
|
2023
|
|
2022
|
|
Change
|
|
2023
|
|
2022
|
|
Change
|
Sales
|
$
|
1,245.0
|
$
|
1,231.9
|
|
1.1 %
|
$
|
3,689.6
|
$
|
3,553.5
|
|
3.8 %
|
Net (Loss)
|
$
|
(4.3)
|
$
|
(229.5)
|
|
98.1 %
|
$
|
(115.7)
|
$
|
(270.4)
|
|
57.2 %
|
Basic Loss per
Share
|
$
|
(0.04)
|
$
|
(1.86)
|
|
97.8 %
|
$
|
(0.95)
|
$
|
(2.18)
|
|
56.4 %
|
Adjusted Operating
Earnings(ii)
|
$
|
70.5
|
$
|
24.1
|
|
192.2 %
|
$
|
135.7
|
$
|
63.9
|
|
112.5 %
|
Adjusted (Loss)
Earnings per Share(ii)
|
$
|
0.13
|
$
|
(0.01)
|
|
nm(iv)
|
$
|
0.01
|
$
|
0.02
|
|
nm(iv)
|
Adjusted EBITDA - Meat
Protein Group(ii)
|
$
|
138.4
|
$
|
100.9
|
|
37.2 %
|
$
|
341.0
|
$
|
302.6
|
|
12.7 %
|
Adjusted EBITDA - Plant
Protein Group(ii)
|
$
|
(9.4)
|
$
|
(24.3)
|
|
61.3 %
|
$
|
(33.0)
|
$
|
(85.0)
|
|
61.2 %
|
Free Cash
Flow(ii)(iii)
|
$
|
139.9
|
$
|
92.9
|
|
50.6 %
|
$
|
160.3
|
$
|
55.1
|
|
190.9 %
|
Construction
Capital(ii)
|
|
|
|
|
|
|
$
|
51.5
|
$
|
713.6
|
|
(92.8) %
|
Net
Debt(ii)
|
|
|
|
|
|
|
$
|
(1,769.5)
|
$
|
(1,522.2)
|
|
(16.2) %
|
Adjusted
EBT(ii)
|
$
|
25.1
|
$
|
8.4
|
|
198.8 %
|
$
|
17.8
|
$
|
26.2
|
|
(32.1) %
|
(i)
|
All financial
measures in millions of dollars except Basic and Adjusted Earnings
per Share.
|
(ii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
(iii)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
(iv)
|
Not
meaningful.
|
Sales for the third quarter of 2023 were $1,245.0 million compared to $1,231.9 million last year, an increase of 1.1%.
Sales growth in the Meat Protein Group was mostly offset by a 16.4%
sales decline in the Plant Protein Group. For more details on sales
performance by operating segment, please refer to Operating
Review.
Year-to-date sales for 2023 were $3,689.6
million compared to $3,553.5
million last year, an increase of 3.8%. Meat Protein Group
sales grew 4.3% which more than offset the 14.5% decline in the
Plant Protein Group during the same period.
Net loss for the third quarter of 2023 was $4.3 million ($0.04
loss per basic share) compared to a loss of $229.5 million ($1.86 loss per basic share) last year. The prior
year net loss included a $190.9
million one-time non-cash impairment charge related to the
Plant Protein Group, as well as a $31.5
million decrease in the fair value of biological assets
compared to a $0.3 million increase
in 2023.The Meat Protein Group showed improved commercial results
and pork market conditions, partly offset by cost inflation, along
with increased start up costs. The Plant Protein Group delivered
improved margins along with lower Selling, General, and
Administrative ("SG&A") spending as the segment continues to
reduce costs as part of its short term strategy. In addition,
current year results were negatively impacted by higher interest
expense with increased rates and higher debt largely to fund
strategic capital expenditures, and by income tax expenses, which
were a recovery in the prior year.
Year-to-date net loss for 2023 was $115.7
million ($0.95 loss per basic
share) compared to loss of $270.4
million ($2.18 loss per basic
share) last year due to similar factors as noted above, with the
exception of increased pork market headwinds for the year to
date.
Adjusted Operating Earnings for the third quarter of 2023 were
$70.5 million compared to
$24.1 million last year, and Adjusted
Earnings per Share for the third quarter of 2023 was $0.13 compared to loss of $0.01 last year. The increase was a result of
improved commercial results and pork market conditions, partly
offset by cost inflation.
Year-to-date Adjusted Operating Earnings for 2023 were
$135.7 million compared to
$63.9 million last year, and Adjusted
Earnings per Share for 2023 were a loss of $0.01 compared to earnings of $0.02 last year due to similar factors as noted
above, with the exception of increased pork market headwinds for
the year to date.
Adjusted Earnings Before Taxes ("Adjusted EBT") for the third
quarter of 2023 were $25.1 million
compared to $8.4 million last year.
Adjusted EBT was driven by improved commercial performance and pork
market conditions, partly offset by cost inflation in the Meat
Protein Group, as well as improved margins in the Plant Protein
group. This was partly offset by higher interest expense with
increased rates and higher debt largely to fund strategic capital
expenditures.
Year-to-date Adjusted EBT for 2023 were a loss of $17.8 million compared to earnings of
$26.2 million last year due to
similar factors as noted above with the exception of increased pork
market headwinds for the year to date.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items
are excluded from the discussions of underlying earnings
performance as they are not representative of ongoing operational
activities. Refer to the section entitled Non-IFRS Financial
Measures at the end of this news release for a description and
reconciliation of all non-IFRS financial measures.
|
Operating Review
The Company has two reportable segments. These segments offer
different products, with separate organizational structures,
brands, and financial and marketing strategies. The Company's chief
operating decision makers regularly review internal reports for
these businesses. Performance of the Meat Protein Group is based on
profitable revenue growth, Adjusted Operating Earnings,
Adjusted EBITDA, and Adjusted EBT while the performance of
the Plant Protein Group in the short term is focused on obtaining
Adjusted EBITDA neutral results.
The following table summarizes the Company's sales, gross profit
(loss), SG&A, Adjusted Operating Earnings, Adjusted EBITDA,
Adjusted EBITDA Margin, and Adjusted EBT by operating segment for
the three months ended September 30, 2023 and
September 30, 2022.
|
|
Three months ended
September 30, 2023
|
|
Three months ended
September 30, 2022
|
($
millions)(i) (Unaudited)
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
Sales
|
$
|
1,211.0
|
36.4
|
(2.5)
|
$
|
1,245.0
|
$
|
1,194.5
|
43.6
|
(6.2)
|
$
|
1,231.9
|
Gross profit
(loss)
|
$
|
143.5
|
(2.2)
|
4.5
|
$
|
145.9
|
$
|
125.6
|
(9.8)
|
(33.3)
|
$
|
82.5
|
Selling, general and
administrative
expenses
|
$
|
83.0
|
11.9
|
—
|
$
|
94.9
|
$
|
82.9
|
19.9
|
—
|
$
|
102.8
|
Adjusted Operating
Earnings(iii)
|
$
|
84.6
|
(14.1)
|
—
|
$
|
70.5
|
$
|
53.6
|
(29.5)
|
—
|
$
|
24.1
|
Adjusted
EBITDA(iii)
|
$
|
138.4
|
(9.4)
|
—
|
$
|
129.0
|
$
|
100.9
|
(24.3)
|
—
|
$
|
76.7
|
Adjusted EBITDA
Margin(iii)
|
|
11.4 %
|
(25.7) %
|
n/a
|
|
10.4 %
|
|
8.5 %
|
(55.6) %
|
n/a
|
|
6.2 %
|
Adjusted
EBT(iii)
|
$
|
39.4
|
(14.3)
|
—
|
$
|
25.1
|
$
|
40.5
|
(32.1)
|
—
|
$
|
8.4
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments or are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
The following table summarizes the Company's sales, gross profit
(loss), SG&A, Adjusted Operating Earnings, Adjusted
EBITDA, Adjusted EBITDA Margin, and Adjusted EBT by operating
segment for the nine months ended September 30, 2023 and
September 30, 2022.
|
Nine months ended
September 30, 2023
|
Nine months ended
September 30, 2022
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
3,591.6
|
110.5
|
(12.5)
|
$
3,689.6
|
$
3,444.1
|
129.3
|
(19.8)
|
$
3,553.5
|
Gross profit
(loss)
|
$
354.2
|
(7.3)
|
(31.0)
|
$
315.9
|
$ 392.5
|
(26.2)
|
(42.8)
|
$ 323.6
|
Selling, general and
administrative
expenses
|
$
264.0
|
39.8
|
—
|
$
303.8
|
$ 258.9
|
77.0
|
—
|
$ 335.9
|
Adjusted Operating
Earnings(iii)
|
$
182.8
|
(47.1)
|
—
|
$
135.7
|
$ 162.3
|
(98.4)
|
—
|
$
63.9
|
Adjusted
EBITDA(iii)
|
$
341.0
|
(33.0)
|
(0.6)
|
$
307.4
|
$ 302.6
|
(85.0)
|
—
|
$ 217.6
|
Adjusted EBITDA
Margin(iii)
|
9.5 %
|
(29.8) %
|
n/a
|
8.3 %
|
8.8 %
|
(65.7) %
|
n/a
|
6.1 %
|
Adjusted
EBT(iii)
|
$
66.3
|
(47.8)
|
(0.6)
|
$
17.8
|
$ 132.3
|
(106.1)
|
—
|
$
26.2
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated
cost of goods sold, changes in the fair value of biological assets
and derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments or are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, snack kits, value-added
fresh pork and poultry products that are sold to retail,
foodservice and industrial channels, and agricultural operations in
pork and poultry. The Meat Protein Group includes leading brands
such as Maple Leaf®, Maple Leaf Prime®, Maple
Leaf Natural Selections®, Schneiders®,
Schneiders® Country Naturals®,
Mina®, Greenfield Natural Meat Co.®, and
other leading regional brands.
Sales for the third quarter of 2023 increased 1.4% to
$1,211.0 million compared to
$1,194.5 million last year. Sales
growth was driven by pricing action implemented in prior quarters
to reflect higher input costs, mix-shift and favourable foreign
exchange. These factors were partly offset by lower volumes.
Year-to-date sales for 2023 increased 4.3% to $3,591.6 million compared to $3,444.1 million last year. Sales growth was
driven by factors consistent with those mentioned above.
Gross profit for the third quarter of 2023 was $143.5 million (gross margin(i)
of 11.8%) compared to $125.6 million
(gross margin(i) of 10.5%) last year. Gross
profit was positively impacted by pricing action to catch up to
inflation, and improved pork market conditions including in
Japan, partially offset by cost
inflation, lower volume, and startup expenses. Gross profit for the
third quarter included start-up expenses of $24.1 million (2022: $11.0
million) associated with Construction Capital projects,
which are excluded in the calculation of Adjusted Operating
Earnings.
Year-to-date gross profit for 2023 was $354.2 million (gross margin(i)
of 9.9%) compared to $392.5 million
(gross margin(i) of 11.4%) last year. Gross
profit was negatively impacted by pork market headwinds, cost
inflation, start up expenses, and lower volume, partially offset by
pricing action to address inflation. Gross profit year to date
included start-up expenses of $92.7
million (2022: $28.7 million)
associated with Construction Capital projects, which are excluded
in the calculation of Adjusted Operating Earnings.
SG&A expenses for the third quarter of 2023 were consistent
with the prior year, at $83.0 million
compared to $82.9 million last
year.
Year-to-date SG&A expenses for 2023 were $264.0 million compared to $258.9 million last year. The slight increase in
SG&A expenses was driven by higher people costs from
stabilizing staffing levels and discretionary spend, partially
offset by lower advertising and promotional expenses.
Adjusted Operating Earnings for the third quarter of 2023 were
$84.6 million compared to
$53.6 million last year, driven by
factors noted above.
Year-to-date Adjusted Operating Earnings for 2023 were
$182.8 million compared to
$162.3 million last year, consistent
with factors noted above.
Adjusted EBITDA for the third quarter of 2023 were $138.4 million compared to $100.9 million last year, driven by factors
consistent with those noted above as well as benefits from the
London poultry plant and Bacon
Centre of Excellence. Adjusted EBITDA Margin for the third quarter
was 11.4% compared to 8.5% last year, driven by factors consistent
with those noted above.
Year-to-date Adjusted EBITDA for 2023 were $341.0 million compared to $302.6 million last year, driven by factors
consistent with those noted above. Year-to-date Adjusted EBITDA
Margin for 2023 was 9.5% compared to 8.8% last year, also driven by
factors consistent with those noted above.
During the third quarter of 2023 the Meat Protein Group Adjusted
EBT were $39.4 million compared to
$40.5 million last year, driven by
factors consistent with those noted above, as well as a
$28.5 million increase in interest
expense as a result of increased interest rates and higher debt,
and increased depreciation expense all related to continued capital
investment.
Year-to-date Adjusted EBT were $66.3
million compared to $132.3
million last year, driven by factors consistent with those
noted above, as well as an $84.1
million increase in interest expense as a result of
increased interest rates and higher debt, and increased
depreciation expense all related to continued capital
investment.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands
Lightlife® and Field Roast™.
Sales for the third quarter of 2023 decreased 16.4% to
$36.4 million compared to
$43.6 million last year. Excluding
the impact of foreign exchange, sales decreased 18.5%, driven by
lower volumes across all channels, partially offset by pricing
action implemented in prior quarters to mitigate inflation.
Year-to-date sales for 2023 decreased 14.5% to $110.5 million compared to $129.3 million last year. Excluding the impact of
foreign exchange, sales decreased 18.5%, consistent with factors
noted above.
Gross profit for the third quarter of 2023 was a loss of
$2.2 million (gross margin
loss(i) of 5.9%) compared to a loss of
$9.8 million (gross margin
loss(i) of 22.5%) last year. The improvement
in gross margin was driven by operational improvements, higher
pricing, and reduction in start-up expenses, partially offset by
lower volumes. Gross profit for the third quarter of 2022 included
start-up expenses of $0.2 million
associated with Construction Capital projects which are excluded in
the calculation of Adjusted Operating Earnings that were not
repeated in the third quarter of 2023.
Year-to-date gross profit for 2023 was a loss of $7.3 million (gross margin
loss(i) of 6.6%) compared to a loss of
$26.2 million (gross margin
loss(i) of 20.2%) last year. The increase in
gross profit was also driven by factors consistent with those noted
above. Year-to-date gross profit for 2022 included start-up
expenses of $4.8 million associated
with Construction Capital projects which are excluded in the
calculation of Adjusted Operating Earnings, that were not repeated
in 2023.
SG&A expenses for the third quarter of 2023 were
$11.9 million (32.6% of sales)
compared to $19.9 million (45.5% of
sales) last year. The decrease in SG&A was largely driven by
lower advertising and promotional expenses and lower headcount
expenses.
Year-to-date SG&A expenses for 2023 were $39.8 million (36.0% of sales) compared to
$77.0 million (59.5% of sales) last
year. The decrease in SG&A was driven by factors consistent
with those noted above, and well as lower consulting costs.
Adjusted Operating Earnings for the third quarter of 2023 were a
loss of $14.1 million compared to a
loss of $29.5 million last year. The
improvement in Adjusted Operating Earnings is consistent with the
factors noted above.
Year-to-date Adjusted Operating Earnings for 2023 were a loss of
$47.1 million compared to a loss of
$98.4 million last year. The
improvement in Adjusted Operating Earnings is consistent with the
factors noted above.
Adjusted EBITDA for the third quarter of 2023 were a loss of
$9.4 million compared to a loss of
$24.3 million last year, driven by
factors consistent with those noted above. Adjusted EBITDA Margin
for the third quarter was a loss of 25.7% compared to a loss of
55.6% last year, also driven by factors consistent with those noted
above.
Year-to-date Adjusted EBITDA for the third quarter of 2023 were
a loss of $33.0 million compared to a
loss of $85.0 million last year,
driven by factors consistent with those noted above. Year-to-date
Adjusted EBITDA Margin for the third quarter was a loss of 29.8%
compared to a loss of 65.7% last year, also driven by factors
consistent with those noted above.
(i)
Gross margin is defined as gross profit (loss) divided by
sales.
|
Other Matters
On November 1, 2023, the Board of
Directors approved a quarterly dividend of $0.21 per share, $0.84 per share on an annual basis, payable
December 29, 2023 to shareholders of
record at the close of business December 8,
2023. Unless indicated otherwise by the Company at or before
the time the dividend is paid, the dividend will be considered an
eligible dividend for the purposes of the "Enhanced Dividend Tax
Credit System". The Board of Directors has also approved the
issuance of common shares from treasury at a two percent discount
under the Company's Dividend Reinvestment Plan ("DRIP"). Under the
DRIP, investors holding the Company's common shares can receive
common shares instead of cash dividend payments. Further details,
including how to enroll in the program, are available
at https://www.mapleleaffoods.com/investors/stock-information/.
Conference Call
A conference call will be held at 8:00 a.m. ET on
November 2, 2023, to review Maple
Leaf Foods' third quarter financial results. To participate in the
call, please dial 416-764-8650 or 1-888-664-6383. For those unable
to participate, playback will be made available an hour after the
event at 416-764-8677 or 1-888-390-0541 (Passcode: 113305#).
A webcast of the third quarter conference call will also be
available at: https://www.mapleleaffoods.com.
The Company's full consolidated interim financial statements
("Consolidated Interim Financial Statements") and related
Management's Discussion and Analysis are available on the Company's
website.
An investor presentation related to the Company's third quarter
financial results is available at www.mapleleaffoods.com and can be
found under Presentations and Webcasts on the Investors page.
Outlook
Maple Leaf Foods is a leading consumer protein company,
supported by a portfolio of market leading brands. Over the last
several years, the Company has developed a foundation to pursue
compelling growth vectors across its business and to create value
for all stakeholders.
Meat Protein Group
In Meat Protein, the Company's strategy is to drive profitable
growth. Given the unprecedented market dynamics, marked by a
challenging post-pandemic economy, the conflict in Europe, high inflation and significant market
disruption, Maple Leaf Foods expects that its Meat Protein Group
will achieve the following:
- Mid-single digit sales growth in 2023, supported by brand
leadership, and growth in international markets.
- Adjusted EBITDA Margin expansion to a 14% - 16% target range
once markets normalize.
Plant Protein Group
- In late 2021, the Company announced that it was re-evaluating
its outlook for the Plant Protein Group and launching a
comprehensive review of the overall plant protein category. This
decision was driven by a pronounced slowdown in growth rates in the
category, particularly in the second half of the year, which fueled
the Company's imperative to identify and thoroughly assess the
causes, near and long-term trends, and overall implications. The
Company's analysis to date confirms that the very high category
growth rates previously predicted by many industry experts are
unlikely to be achieved given current customer feedback,
experience, buy rates and household penetration. Based on this
information, the Company believes that the category will continue
to grow at more modest, but still attractive rates. The Company
estimates that the category will grow at an average annual rate of
10% to 15%, making it a $6 billion to
$10 billion market by 2030.
Accordingly, the Company has pivoted its strategy and investment
thesis for the Plant Protein Group and has set a new goal to
deliver neutral Adjusted EBITDA in the latter half of 2023. Work is
ongoing to implement this pivot. The Company expects steady
Adjusted EBITDA improvement to continue throughout the year.
Capital
- The Company currently estimates its capital expenditures for
2023 will be approximately $200
million, down from previous expectations mainly due to
timing of projects and disciplined capital management. Additionally
the Company estimates its capital expenditures for 2024 will be in
the range of $170 million to
$190 million, based on expected
timing of projects and continued discipline in capital
management.
- The Company expects the London,
Ontario poultry facility to start to deliver approximately
$100 million annually of additional
Adjusted EBITDA once fully ramped up which is expected to be by the
end of 2023. Additionally, the Company expects the Bacon Centre of
Excellence in Winnipeg, Manitoba
to contribute approximately $30
million annually of additional Adjusted EBITDA once fully
ramped up by the end of 2023.
The ongoing effects of the post-pandemic economy induced supply
chain disruptions and the war in Ukraine are unpredictable and may impact a
number of factors that drive growth in the business, including:
- Agricultural commodity and foreign exchange markets;
- Inflationary cost pressures;
- Disruptions in the global supply chain;
- Availability of labour; and
- Demand for products and changes in product mix.
The execution of the Company's financial and operational
priorities are embedded in a commitment to deliver shared value for
the benefit of all stakeholders. The Company's guiding pillars to
be the "Most Sustainable Protein Company on Earth" include Better
Food, Better Care, Better Communities, Better Planet and are core
to how Maple Leaf Foods conducts itself. To that end, the Company's
priorities include:
- Better Food - leading the real food movement and
transitioning key brands to 100% "raised without antibiotics".
- Better Care - further advancement of animal care, after
achieving our transition of all sows under management to open
housing systems in 2021, we have an ongoing program to convert any
new sow barns that we acquire.
- Better Communities - investing a minimum of
approximately 1% of pre-tax profit to advance sustainable food
security.
- Better Planet - continuing to amplify its commitment to
carbon neutrality, while focusing on eliminating waste in any
resources it consumes, including food, energy, water, packaging,
and time.
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Adjusted EBT, Construction Capital, Net
Debt, Free Cash Flow and Return on Net Assets. Management believes
that these non-IFRS measures provide useful information to
investors in measuring the financial performance of the Company for
the reasons outlined below. These measures do not have a
standardized meaning prescribed by IFRS and therefore they may not
be comparable to similarly titled measures presented by other
publicly traded companies and should not be construed as an
alternative to other financial measures determined in accordance
with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA, Adjusted EBITDA
Margin and Adjusted EBT
Adjusted Operating Earnings, Adjusted EBITDA, Adjusted EBITDA
Margin and Adjusted EBT are non-IFRS measures used by Management to
evaluate financial operating results. Adjusted Operating Earnings
is defined as earnings before other income, income taxes and
interest expense adjusted for items that are not considered
representative of ongoing operational activities of the business
and certain items where the economic impact of the transactions
will be reflected in earnings in future periods when the underlying
or related asset is sold or transferred. Adjusted EBITDA is defined
as Adjusted Operating Earnings plus depreciation and intangible
asset amortization, adjusted for items included in other expense
that are considered representative of ongoing operational
activities of the business. Adjusted EBITDA Margin is calculated as
Adjusted EBITDA divided by sales. Adjusted EBT is used annually by
the Company to evaluate its performance and is a component of
calculating bonus entitlements under the Company's short term
incentive plan. It is defined as Adjusted EBITDA, less depreciation
and amortization, and interest expense. Interest expense is
allocated to the operating segments for this metric on a legal
entity basis.
The table below provides a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Interim Financial Statements to Adjusted Operating Earnings,
Adjusted EBITDA and Adjusted EBT for the three and nine months
ended September 30, 2023 as indicated below. Management
believes that these non-IFRS measures are useful in assessing the
performance of the Company's ongoing operations and its ability to
generate cash flows to fund its cash requirements, including the
Company's capital investment program.
|
|
Three months ended
September 30, 2023
|
|
Three months ended
September 30, 2022
|
($
millions)(i) (Unaudited)
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
(Loss) earnings
before income taxes
|
$
|
53.6
|
(18.5)
|
(35.3)
|
$
|
(0.2)
|
$
|
39.4
|
(223.0)
|
(48.2)
|
$
|
(231.8)
|
Interest expense and
other financing costs
|
|
—
|
—
|
40.5
|
|
40.5
|
|
—
|
—
|
14.5
|
|
14.5
|
Impairment of
goodwill
|
|
—
|
—
|
—
|
|
—
|
|
—
|
190.9
|
—
|
|
190.9
|
Other expense
(income)
|
|
7.0
|
0.2
|
(0.6)
|
|
6.6
|
|
1.2
|
2.1
|
0.5
|
|
3.7
|
Restructuring and other
related costs
|
|
(0.2)
|
4.3
|
—
|
|
4.1
|
|
2.0
|
0.4
|
—
|
|
2.3
|
Earnings (loss) from
operations
|
$
|
60.5
|
(14.1)
|
4.5
|
$
|
50.9
|
$
|
42.6
|
(29.7)
|
(33.3)
|
$
|
(20.3)
|
Start-up expenses from
Construction Capital(iii)
|
|
24.1
|
—
|
—
|
|
24.1
|
|
11.0
|
0.2
|
—
|
|
11.2
|
Change in fair value of
biological assets
|
|
—
|
—
|
(0.3)
|
|
(0.3)
|
|
—
|
—
|
31.5
|
|
31.5
|
Unrealized and deferred
loss (gain) on derivative
contracts
|
|
—
|
—
|
(4.3)
|
|
(4.3)
|
|
—
|
—
|
1.8
|
|
1.8
|
Adjusted Operating
Earnings
|
$
|
84.6
|
(14.1)
|
—
|
$
|
70.5
|
$
|
53.6
|
(29.5)
|
—
|
$
|
24.1
|
Depreciation and
amortization
|
|
60.8
|
4.9
|
—
|
|
65.7
|
|
48.5
|
5.2
|
—
|
|
53.8
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
|
(7.0)
|
(0.2)
|
—
|
|
(7.3)
|
|
(1.2)
|
—
|
—
|
|
(1.2)
|
Adjusted
EBITDA
|
$
|
138.4
|
(9.4)
|
—
|
$
|
129.0
|
$
|
100.9
|
(24.3)
|
—
|
$
|
76.7
|
Adjusted EBITDA
Margin
|
|
11.4 %
|
(25.7) %
|
n/a
|
|
10.4 %
|
|
8.5 %
|
(55.6) %
|
n/a
|
|
6.2 %
|
Interest expense and
other financing costs
|
|
(40.4)
|
(0.1)
|
—
|
|
(40.5)
|
|
(11.9)
|
(2.6)
|
—
|
|
(14.5)
|
Interest
income
|
|
2.3
|
—
|
—
|
|
2.3
|
|
—
|
—
|
—
|
|
—
|
Depreciation and
amortization
|
|
(60.8)
|
(4.9)
|
—
|
|
(65.7)
|
|
(48.5)
|
(5.2)
|
—
|
|
(53.8)
|
Adjusted
EBT
|
$
|
39.4
|
(14.3)
|
—
|
$
|
25.1
|
$
|
40.5
|
(32.1)
|
—
|
$
|
8.4
|
(i)
|
Totals may not add due
to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses are
temporary costs as a result of operating new facilities that are or
have been classified as Construction Capital. These costs can
include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production.
|
(iv)
|
Primarily includes
certain costs associated with sustainability projects, gains and
losses on the sale of long-term assets, legal settlements, and
other miscellaneous expenses.
|
|
|
Nine months ended
September 30, 2023
|
|
Nine months ended
September 30, 2022
|
($
millions)(i) (Unaudited)
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
|
Total
|
(Loss) earnings
before income taxes
|
$
|
72.5
|
(63.2)
|
(143.3)
|
$
|
(133.9)
|
$
|
123.7
|
(315.2)
|
(77.8)
|
$
|
(269.4)
|
Interest expense and
other financing costs
|
|
—
|
—
|
109.6
|
|
109.6
|
|
—
|
—
|
33.0
|
|
33.0
|
Impairment of
goodwill
|
|
—
|
—
|
—
|
|
—
|
|
—
|
190.9
|
—
|
|
190.9
|
Other
expense
|
|
10.2
|
0.6
|
2.7
|
|
13.5
|
|
4.6
|
2.2
|
2.1
|
|
8.8
|
Restructuring and other
related costs
|
|
7.4
|
15.5
|
—
|
|
22.9
|
|
5.4
|
19.0
|
—
|
|
24.4
|
Earnings (loss) from
operations
|
$
|
90.1
|
(47.1)
|
(31.0)
|
$
|
12.1
|
$
|
133.6
|
(103.1)
|
(42.8)
|
$
|
(12.3)
|
Start-up expenses from
Construction Capital(iii)
|
|
92.7
|
—
|
—
|
|
92.7
|
|
28.7
|
4.8
|
—
|
|
33.4
|
Change in fair value of
biological assets
|
|
—
|
—
|
28.4
|
|
28.4
|
|
—
|
—
|
42.1
|
|
42.1
|
Unrealized and deferred
loss (gain) on derivative
contracts
|
|
—
|
—
|
2.6
|
|
2.6
|
|
—
|
—
|
0.7
|
|
0.7
|
Adjusted Operating
Earnings
|
$
|
182.8
|
(47.1)
|
—
|
$
|
135.7
|
$
|
162.3
|
(98.4)
|
—
|
$
|
63.9
|
Depreciation and
amortization
|
|
168.4
|
14.7
|
—
|
|
183.1
|
|
144.9
|
13.5
|
—
|
|
158.4
|
Items included in other
income (expense)
representative of ongoing
operations(iv)
|
|
(10.2)
|
(0.6)
|
(0.6)
|
|
(11.4)
|
|
(4.6)
|
(0.1)
|
—
|
|
(4.7)
|
Adjusted
EBITDA
|
$
|
341.0
|
(33.0)
|
(0.6)
|
$
|
307.4
|
$
|
302.6
|
(85.0)
|
—
|
$
|
217.6
|
Adjusted EBITDA
Margin
|
|
9.5 %
|
(29.8) %
|
n/a
|
|
8.3 %
|
|
8.8 %
|
(65.7) %
|
n/a
|
|
6.1 %
|
Interest expense and
other financing costs
|
|
(109.4)
|
(0.2)
|
—
|
|
(109.6)
|
|
(25.4)
|
(7.6)
|
—
|
|
(33.0)
|
Interest
income
|
|
3.1
|
—
|
—
|
|
3.1
|
|
—
|
—
|
—
|
|
—
|
Depreciation and
amortization
|
|
(168.4)
|
(14.7)
|
—
|
|
(183.1)
|
|
(144.9)
|
(13.5)
|
—
|
|
(158.4)
|
Adjusted
EBT
|
$
|
66.3
|
(47.8)
|
(0.6)
|
$
|
17.8
|
$
|
132.3
|
(106.1)
|
—
|
$
|
26.2
|
(i)
|
Totals may not add due
to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments or
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Start-up expenses are
temporary costs as a result of operating new facilities that are or
have been classified as Construction Capital. These costs can
include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production.
|
(iv)
|
Primarily includes
certain costs associated with sustainability projects, gains and
losses on the impairment and sale of long-term assets, legal
settlements, gains and losses on investments, and other
miscellaneous expenses.
|
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under
IFRS in the Consolidated Interim Financial Statements to Adjusted
Earnings per Share for the three and nine months ended September 30 as indicated below. Management
believes this basis is the most appropriate on which to evaluate
financial results as they are representative of the ongoing
operations of the Company.
($ per
share)
(Unaudited)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
2023
|
2022
|
2023
|
2022
|
Basic loss per
share
|
$
|
(0.04)
|
$
|
(1.86)
|
$
|
(0.95)
|
$
|
(2.18)
|
Impairment of
goodwill
|
|
—
|
|
1.54
|
|
—
|
|
1.54
|
Restructuring and other
related costs(i)
|
|
0.03
|
|
0.01
|
|
0.17
|
|
0.17
|
Items included in other
expense not considered
representative of ongoing
operations(ii)
|
|
0.01
|
|
0.02
|
|
0.03
|
|
0.03
|
Start-up expenses from
Construction Capital(iii)
|
|
0.15
|
|
0.07
|
|
0.57
|
|
0.21
|
Change in fair value of
biological assets
|
|
—
|
|
0.19
|
|
0.17
|
|
0.25
|
Change in unrealized
and deferred fair value on
derivatives
|
|
(0.03)
|
|
0.01
|
|
0.02
|
|
—
|
Adjusted Earnings
per Share(iv)
|
$
|
0.13
|
$
|
(0.01)
|
$
|
0.01
|
$
|
0.02
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees and settlements, gains or losses on investment property,
and transaction related costs, net of tax.
|
(iii)
|
Start-up expenses are
temporary costs as a result of operating new facilities that are or
have been classified as Construction Capital. These costs can
include training, product testing, yield and labour efficiency
variances, duplicative overheads and other temporary expenses
required to ramp-up production, net of tax.
|
(iv)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that are not yet operational. It is
defined as investments and related financing charges in projects
over $50.0 million that are related
to longer-term strategic initiatives, with no returns expected for
at least 12 months from commencement of construction and the asset
is re-categorized from Construction Capital once
operational. The current balance of Construction Capital
includes investment in increased further processed poultry capacity
in the Prepared Meats facility in Brampton, Ontario. Investments in capacity at
the Walker Drive facility in Brampton,
Ontario, and the plant protein facility in Indianapolis, Indiana were moved out of
construction capital upon completion during the first quarter of
2022, and the London Poultry facility was moved out of construction
capital during the fourth quarter of 2022 when commercial
production began. The following table is a summary of Construction
Capital activity and debt financing for the periods indicated
below.
($
thousands) (Unaudited)
|
|
2023
|
|
2022
|
Property and
equipment and intangibles at January 1
|
$
|
2,663,985
|
$
|
2,554,483
|
Other capital and
intangible assets at January 1(i)
|
|
2,654,419
|
|
1,811,164
|
Construction Capital
at January 1
|
$
|
9,566
|
$
|
743,319
|
Additions
|
|
8,822
|
|
54,776
|
Transfers from
Construction Capital
|
|
—
|
|
(182,210)
|
Construction
Capital at March 31
|
$
|
18,388
|
$
|
615,885
|
Additions
|
|
18,896
|
|
49,903
|
Construction
Capital at June 30
|
$
|
37,284
|
$
|
665,788
|
Additions
|
|
14,213
|
|
47,789
|
Construction Capital
at September 30(ii)
|
$
|
51,497
|
$
|
713,577
|
Other capital and
intangible assets at September 30(i)
|
|
2,581,318
|
|
1,957,932
|
Property and
equipment and intangibles at September 30
|
$
|
2,632,815
|
$
|
2,671,509
|
|
|
|
|
|
Construction Capital
debt financing(iii)(iv)
|
$
|
50,013
|
$
|
678,635
|
(i)
|
Other capital and
intangible assets consists of property and equipment and
intangibles that do not meet the definition of Construction
Capital.
|
(ii)
|
As at September 30,
2023, the net book value of Construction Capital includes $0.7
million related to intangible assets (September 30, 2022: $3.3
million; December 31, 2022: $0.0 million).
|
(iii)
|
Does not include
$1,024.3 million in capital that has been transferred out but is
still in the start-up stage (2022: $265.2 million).
|
(iv)
|
Assumed to be fully
funded by debt to the extent that the Company has Net Debt
outstanding. Construction Capital debt financing excludes interest
paid and capitalized.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Interim Financial
Statements as at September 30 as
indicated below. The Company calculates Net Debt as cash and cash
equivalents, less long-term debt and bank indebtedness. Management
believes this measure is useful in assessing the amount of
financial leverage employed.
($
thousands)
(Unaudited)
|
|
As at September
30,
|
|
2023
|
|
2022
|
Cash and cash
equivalents
|
$
|
204,598
|
$
|
106,199
|
Current portion of
long-term debt
|
$
|
(398,685)
|
$
|
(712)
|
Long-term
debt
|
|
(1,575,418)
|
|
(1,627,651)
|
Total
debt
|
$
|
(1,974,103)
|
$
|
(1,628,363)
|
Net
Debt
|
$
|
(1,769,505)
|
$
|
(1,522,164)
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance of the
Company's asset base. It is defined as cash provided by operations,
less Maintenance Capital(i) and associated
interest paid and capitalized. The following table calculates Free
Cash Flow for the periods indicated below:
($
thousands)
(Unaudited)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
Cash provided by
operating activities
|
$
|
115,161
|
$
|
75,499
|
$
|
93,871
|
$
|
6,998
|
Maintenance
Capital(i)
|
|
25,190
|
|
17,491
|
|
67,368
|
|
48,360
|
Interest paid and
capitalized related to
Maintenance Capital
|
|
(404)
|
|
(63)
|
|
(890)
|
|
(236)
|
Free Cash
Flow(ii)
|
$
|
139,947
|
$
|
92,927
|
$
|
160,349
|
$
|
55,122
|
(i)
|
Maintenance Capital
is defined as non-discretionary investment required to maintain the
Company's existing operations and competitive position. For the
three and nine months ended September 30, 2023, total capital
spending of $51.3 million and $156.4 million (2022: $78.5 million
and $257.8 million) shown on the Consolidated Statements of Cash
Flows is made up of Maintenance Capital of $25.2 million and $67.4
million (2022: $17.5 million and $48.4 million), and Growth Capital
of $26.1 million and $89.0 million (2022: $61.1 million and $209.4
million). Growth Capital is defined as discretionary investment
meant to create stakeholder value through initiatives that for
example, expand margins, increase capacities or create further
competitive advantage.
|
(ii)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
Return on Net Assets ("RONA")
RONA is calculated by dividing tax effected earnings from
operations (adjusted for items which are not considered
representative of the underlying operations of the business) by
average monthly net assets. Net assets are defined as total assets
(excluding cash and deferred tax assets) less non-interest bearing
liabilities (excluding deferred tax liabilities). Management
believes that RONA is an appropriate basis upon which to evaluate
long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgements and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- assumptions that the major disruptions that influenced the
early post-COVID-19 pandemic recovery, have largely resolved and
are unlikely to recur with the same severity;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, compliance
with credit facility covenants, and availability of capital to fund
growth plans, operating obligations and dividends;
- future performance, including future financial objectives,
goals and targets, category growth analysis, expected capital spend
and expected SG&A expenditures, global pork market dynamics,
Japan export market margin
outlook, labour markets, inflationary pressures (including the
ability to price for inflation);
- potential for a recurrence of a cybersecurity incident on the
Company's systems, business and operations, as well as the ability
to mitigate the financial and operational impacts, the success of
remediation and recovery efforts, the implications of data
exfiltration, and other ongoing risks associated with
cybersecurity;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, plant protein category investment and
performance, market access in China and Japan, capital allocation decisions (including
investment in share repurchases under the NCIB) and investment in
potential growth opportunities and the expected returns associated
therewith;
- the impact of international trade conditions and markets on the
Company's business, including access to markets, implications
associated with the spread of foreign animal disease (such as
African Swine Fever ("ASF")) and other animal diseases such as
Avian Influenza, as well as other social, economic and political
factors that affect trade, including the war in Ukraine;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices and foreign exchange impacts on
the Company's operations and financial performance, including the
use and effectiveness of hedging instruments;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives, cost reduction initiatives, and service
levels (including service level penalties);
- the implementation, cost and impact of environmental
sustainability initiatives, the ability of the Company to achieve
its sustainability objectives, changing climate and sustainability
laws and regulation, changes in customer and consumer expectations
related to sustainability matters, as well as the anticipated
future cost of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the adaptations in operations, supply
chain, customer and consumer behaviour, economic patterns
(including but not limited to global pork markets), foreign
exchange rates, international trade dynamics and access to capital,
including possible presence or absence of structural changes
associated with economic recovery since the pandemic;
- the competitive environment, associated market conditions and
market share metrics, category growth or contraction, the expected
behaviour of competitors and customers and trends in consumer
preferences;
- the success of the Company's business strategy, including
execution of the strategy in the Meat Protein Group, the execution
of the Adjusted EBITDA neutral strategy for the Plant Protein Group
and the relationship between pricing, inflation, volume and sales
of the Company's products;
- prevailing commodity prices (especially in pork and feed
markets), interest rates, tax rates and exchange rates;
- potential ongoing impacts of the cybersecurity incident, the
potential for a future incident, the risks associated with data
exfiltration, the availability of insurance, the effectiveness of
remediation and prevention activities, third party activities,
ongoing impacts, customer, consumer and supplier responses and
regulatory considerations;
- the economic condition of and the sociopolitical dynamics
between Canada, the U.S.,
Japan and China, and the ability of the Company to
access markets and source ingredients and other inputs in light of
global sociopolitical disruption, and the ongoing impact of the war
in Ukraine on international
relations, trade and markets;
- the spread of foreign animal disease (including ASF and Avian
Influenza), preparedness strategies to manage such spread, and
implications for all protein markets;
- the availability of and access to capital to fund future
capital requirements and ongoing operations;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain sales
volumes, turnover of inventories and turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- presence or absence of adaptations or structural changes
arising since the economic recovery from the pandemic which may
have implications for the operations and financial performance of
the Company, as well the ongoing implications for macro
socio-economic trends;
- macro economic trends, including inflation, recessionary
indicators, labour availability and labour market dynamics and
international trade trends (including global pork markets);
- the results of the Company's execution of its business plans,
the degree to which benefits are realized or not, and the timing
associated realizing those benefits, including the implications on
cash flow;
- competition, market conditions, and the activities of
competitors and customers, including the expansion or contraction
of key categories. pork market dynamics and Japan export margins;
- cybersecurity and maintenance and operation of the Company's
information systems, processes and data, recovery, restoration and
long term impacts of the cybersecurity event, the risk of future
cybersecurity events, actions of third parties, risks of data
exfiltration, effectiveness of business continuity planning and
execution, and availability of insurance;
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets and supplies, as well
as social, political and economic dynamics, including the war in
Ukraine;
- operating performance, including manufacturing operating
levels, fill rates and penalties;
- availability of and access to capital, and compliance with
credit facility covenants;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and
regulatory variables, all of which impact expected returns on
investment;
- food safety, consumer liability and product recalls;
- climate change, climate regulation and the Company's
sustainability performance;
- strategic risk management, including execution of the Adjusted
EBITDA neutral strategy in the plant protein segment;
- acquisitions and divestitures;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange
rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2022.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin growth in the Meat Protein
Group, and Adjusted EBITDA target in the Plant Protein Group
(including the timing, pace and impact of restructuring
activities), may be considered to be financial outlooks for
purposes of applicable securities legislation. These financial
outlooks are presented to evaluate potential future earnings and
anticipated future uses of cash flows and may not be appropriate
for other purposes. Readers should not assume these financial
outlooks will be achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2022,
that is available on SEDAR+ at www.sedarplus.ca. The reader should
review such section in detail. Additional information concerning
the Company, including the Company's Annual Information Form, is
available on SEDAR+ at www.sedarplus.ca.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral company with a
vision to be the most sustainable protein company on earth,
responsibly producing food products under leading brands including
Maple Leaf®, Maple Leaf Prime®, Maple Leaf
Natural Selections®, Schneiders®,
Schneiders® Country Naturals®,
Mina®, Greenfield Natural Meat Co.®,
Lightlife® and Field Roast™. The Company employs
approximately 14,000 people and does business primarily in
Canada, the U.S. and
Asia. The Company is headquartered in Mississauga, Ontario and its shares trade on
the Toronto Stock Exchange (MFI).
Consolidated Interim Balance Sheets
(In thousands of
Canadian dollars)
(Unaudited)
|
As at September
30,
2023
|
As at September
30, 2022(i)
|
As at December 31,
2022(i)
|
As at January 1,
2022(i)
|
ASSETS
|
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
204,598
|
$
|
106,199
|
$
|
91,076
|
$
|
162,031
|
Accounts
receivable
|
|
195,196
|
|
180,301
|
|
167,611
|
|
167,082
|
Notes
receivable
|
|
35,659
|
|
61,301
|
|
48,556
|
|
33,294
|
Inventories
|
|
546,747
|
|
494,477
|
|
485,979
|
|
409,677
|
Biological
assets
|
|
112,029
|
|
112,237
|
|
144,169
|
|
138,209
|
Income taxes
recoverable
|
|
87,371
|
|
18,997
|
|
57,497
|
|
1,830
|
Prepaid expenses and
other assets
|
|
28,677
|
|
56,104
|
|
50,266
|
|
24,988
|
Assets held for
sale
|
|
604
|
|
604
|
|
604
|
|
—
|
Total current
assets
|
$
|
1,210,881
|
$
|
1,030,220
|
$
|
1,045,758
|
$
|
937,111
|
Property and
equipment
|
|
2,281,032
|
|
2,303,981
|
|
2,303,424
|
|
2,189,165
|
Right-of-use
assets
|
|
150,510
|
|
165,729
|
|
159,199
|
|
161,662
|
Investments
|
|
23,489
|
|
23,912
|
|
23,712
|
|
22,326
|
Investment
property
|
|
19,489
|
|
5,289
|
|
5,289
|
|
5,289
|
Employee
benefits
|
|
47,735
|
|
—
|
|
12,531
|
|
—
|
Other long-term
assets
|
|
9,522
|
|
19,995
|
|
12,493
|
|
9,780
|
Deferred tax
asset
|
|
42,639
|
|
52,165
|
|
42,541
|
|
39,907
|
Goodwill
|
|
477,353
|
|
477,353
|
|
477,353
|
|
658,673
|
Intangible
assets
|
|
351,783
|
|
367,528
|
|
360,561
|
|
365,318
|
Total long-term
assets
|
$
|
3,403,552
|
$
|
3,415,952
|
$
|
3,397,103
|
$
|
3,452,120
|
Total
assets
|
$
|
4,614,433
|
$
|
4,446,172
|
$
|
4,442,861
|
$
|
4,389,231
|
LIABILITIES AND
EQUITY
|
|
|
|
|
|
|
|
|
Accounts payable and
accruals
|
$
|
581,625
|
$
|
549,723
|
$
|
485,114
|
$
|
526,189
|
Current portion of
provisions
|
|
14,437
|
|
39,939
|
|
42,589
|
|
842
|
Current portion of
long-term debt
|
|
398,685
|
|
712
|
|
921
|
|
5,176
|
Current portion of
lease obligations
|
|
38,177
|
|
38,417
|
|
38,321
|
|
31,375
|
Income taxes
payable
|
|
833
|
|
1,084
|
|
2,311
|
|
23,853
|
Other current
liabilities
|
|
14,591
|
|
50,532
|
|
64,684
|
|
81,265
|
Total current
liabilities
|
$
|
1,048,348
|
$
|
680,407
|
$
|
633,940
|
$
|
668,700
|
Long-term
debt
|
|
1,575,418
|
|
1,627,651
|
|
1,709,493
|
|
1,247,073
|
Lease
obligations
|
|
137,904
|
|
149,011
|
|
144,569
|
|
144,391
|
Employee
benefits
|
|
58,798
|
|
74,808
|
|
64,280
|
|
97,629
|
Provisions
|
|
2,272
|
|
7,113
|
|
3,799
|
|
44,650
|
Other long-term
liabilities
|
|
948
|
|
1,304
|
|
1,841
|
|
1,057
|
Deferred tax
liability
|
|
243,520
|
|
173,174
|
|
221,606
|
|
147,060
|
Total long-term
liabilities
|
$
|
2,018,860
|
$
|
2,033,061
|
$
|
2,145,588
|
$
|
1,681,860
|
Total
liabilities
|
$
|
3,067,208
|
$
|
2,713,468
|
$
|
2,779,528
|
$
|
2,350,560
|
Shareholders'
equity
|
|
|
|
|
|
|
|
|
Share
capital
|
$
|
866,443
|
$
|
852,872
|
$
|
850,086
|
$
|
847,016
|
Retained
earnings
|
|
652,837
|
|
880,314
|
|
809,616
|
|
1,212,244
|
Contributed
surplus
|
|
1,671
|
|
—
|
|
—
|
|
5,371
|
Accumulated other
comprehensive
income
|
|
33,457
|
|
25,434
|
|
29,547
|
|
286
|
Treasury
shares
|
|
(7,183)
|
|
(25,916)
|
|
(25,916)
|
|
(26,246)
|
Total shareholders'
equity
|
$
|
1,547,225
|
$
|
1,732,704
|
$
|
1,663,333
|
$
|
2,038,671
|
Total liabilities
and equity
|
$
|
4,614,433
|
$
|
4,446,172
|
$
|
4,442,861
|
$
|
4,389,231
|
(i) Restated, refer to
Note 3 of the Consolidated Interim Financial
Statements.
|
Consolidated Interim Statements of Net Loss
(In thousands of
Canadian dollars, except share
amounts)
(Unaudited)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
|
|
|
|
|
|
|
Sales
|
$
|
1,245,021
|
$
|
1,231,855
|
$
|
3,689,574
|
$
|
3,553,541
|
Cost of goods
sold
|
|
1,099,164
|
|
1,149,394
|
|
3,373,675
|
|
3,229,978
|
Gross profit
|
$
|
145,857
|
$
|
82,461
|
$
|
315,899
|
$
|
323,563
|
Selling, general and
administrative expenses
|
|
94,908
|
|
102,800
|
|
303,805
|
|
335,865
|
Earnings (loss) before
the following:
|
$
|
50,949
|
$
|
(20,339)
|
$
|
12,094
|
$
|
(12,302)
|
Restructuring and other
related costs
|
|
4,135
|
|
2,332
|
|
22,910
|
|
24,389
|
Other
expense
|
|
6,593
|
|
3,733
|
|
13,467
|
|
8,809
|
Impairment of
goodwill
|
|
—
|
|
190,911
|
|
—
|
|
190,911
|
Earnings (loss) before
interest and income taxes
|
$
|
40,221
|
$
|
(217,315)
|
$
|
(24,283)
|
$
|
(236,411)
|
Interest expense and
other financing costs
|
|
40,467
|
|
14,494
|
|
109,624
|
|
32,996
|
(Loss) before income
taxes
|
$
|
(246)
|
$
|
(231,809)
|
$
|
(133,907)
|
$
|
(269,407)
|
Income tax expense
(recovery)
|
|
4,028
|
|
(2,333)
|
|
(18,251)
|
|
994
|
Net loss
|
$
|
(4,274)
|
$
|
(229,476)
|
$
|
(115,656)
|
$
|
(270,401)
|
|
|
|
|
|
|
|
|
|
(Loss) earnings per
share attributable to common
shareholders:
|
|
|
|
|
|
|
|
|
Basic loss per
share
|
$
|
(0.04)
|
$
|
(1.86)
|
$
|
(0.95)
|
$
|
(2.18)
|
Diluted loss per
share
|
$
|
(0.04)
|
$
|
(1.86)
|
$
|
(0.95)
|
$
|
(2.18)
|
Weighted average number
of shares (millions):
|
|
|
|
|
|
|
|
|
Basic
|
|
122.0
|
|
123.7
|
|
121.7
|
|
123.9
|
Diluted
|
|
122.0
|
|
123.7
|
|
121.7
|
|
123.9
|
Consolidated Interim Statements of Other
Comprehensive
Income (Loss)
(In thousands of
Canadian dollars)
(Unaudited)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
|
|
|
|
|
|
|
Net loss
|
$
|
(4,274)
|
$
|
(229,476)
|
$
|
(115,656)
|
$
|
(270,401)
|
Other comprehensive
income (loss)
|
|
|
|
|
|
|
|
|
Actuarial (losses)
gains that will not be reclassified
to profit or loss (Net of tax of $1.4 million and
$11.0 million; 2022: $6.0 million and $7.6 million)
|
$
|
3,990
|
$
|
(17,221)
|
$
|
31,893
|
$
|
22,185
|
Change in revaluation
surplus (Net of tax of $2.5 million and $4.2 million; 2022:
$0.0 million and $0.0 million)
|
|
11,040
|
|
—
|
|
18,033
|
|
—
|
Total items that will
not be reclassified to profit or loss
|
$
|
15,030
|
$
|
(17,221)
|
$
|
49,926
|
$
|
22,185
|
Items that are or may
be reclassified subsequently to
profit or loss:
|
|
|
|
|
|
|
|
|
Change in accumulated
foreign currency translation
adjustment (Net of tax of $0.0 million and $0.0
million; 2022: $0.0 million and $0.0 million)
|
|
8,940
|
|
26,976
|
|
(180)
|
|
35,068
|
Change in foreign
exchange on long-term debt
designated as a net investment hedge (Net of tax
of $1.3 million and $0.1 million; 2022: $3.9 million
and $5.0 million)
|
|
(7,220)
|
|
(20,825)
|
|
(602)
|
|
(26,350)
|
Change in cash flow
hedges (Net of tax of $1.0 million and $2.7 million; 2022: $1.6
million and
$5.6 million)
|
|
(2,489)
|
|
4,543
|
|
(6,378)
|
|
16,430
|
Total items that are or
may be reclassified subsequently to profit or loss
|
$
|
(769)
|
$
|
10,694
|
$
|
(7,160)
|
$
|
25,148
|
Total other
comprehensive income (loss)
|
$
|
14,261
|
$
|
(6,527)
|
$
|
42,766
|
$
|
47,333
|
Comprehensive (loss)
income
|
$
|
9,987
|
$
|
(236,003)
|
$
|
(72,890)
|
$
|
(223,068)
|
Consolidated Interim Statements of Changes in Total
Equity
|
|
|
|
|
Accumulated other
comprehensive income (loss)
|
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment(i)
|
Unrealized
gains and
losses on
cash flow hedges(i)
|
Unrealized
gains on fair
value of
investments(i)
|
Revaluation
surplus(iii)
|
Treasury
shares
|
|
Total
equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December
31, 2022(iii)
|
$
|
850,086
|
809,616
|
—
|
10,972
|
12,885
|
2,945
|
2,745
|
(25,916)
|
$
|
1,663,333
|
Net loss
|
|
—
|
(115,656)
|
—
|
—
|
—
|
—
|
—
|
—
|
|
(115,656)
|
Other
comprehensive income (loss)(ii)
|
|
—
|
31,893
|
—
|
(782)
|
(6,378)
|
—
|
18,033
|
—
|
|
42,766
|
Dividends declared
($0.63 per share)
|
|
5,052
|
(76,964)
|
—
|
—
|
—
|
—
|
—
|
—
|
|
(71,912)
|
Share-based
compensation expense
|
|
—
|
—
|
7,733
|
—
|
—
|
—
|
—
|
—
|
|
7,733
|
Deferred taxes on
share-based compensation
|
|
—
|
—
|
1,100
|
—
|
—
|
—
|
—
|
—
|
|
1,100
|
Exercise of stock
options
|
|
6,792
|
—
|
(1,363)
|
—
|
—
|
—
|
—
|
—
|
|
5,429
|
Shares
re-purchased
|
|
(4,498)
|
—
|
(11,595)
|
—
|
—
|
—
|
—
|
—
|
|
(16,093)
|
Sale of investment
property
|
|
—
|
6,963
|
—
|
—
|
—
|
—
|
(6,963)
|
—
|
|
—
|
Sale of treasury
stock
|
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
9,841
|
|
9,841
|
Settlement of
share-based compensation
|
|
—
|
(3,015)
|
(15,192)
|
—
|
—
|
—
|
—
|
8,892
|
|
(9,315)
|
Change in obligation
for repurchase of shares
|
|
9,011
|
—
|
20,988
|
—
|
—
|
—
|
—
|
—
|
|
29,999
|
Balance at September
30, 2023
|
$
|
866,443
|
652,837
|
1,671
|
10,190
|
6,507
|
2,945
|
13,815
|
(7,183)
|
$
|
1,547,225
|
|
|
|
|
|
|
|
|
|
Accumulated other
comprehensive income (loss)(i)
|
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign
currency
translation
adjustment(i)
|
Unrealized
gains and
losses on
cash flow
hedges(i)
|
Unrealized
gains on fair
value of
investments(i)
|
Revaluation
surplus(iii)
|
Treasury
shares
|
|
Total
equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1,
2022(iii)
|
$
|
847,016
|
1,212,244
|
5,371
|
2,037
|
(7,441)
|
2,945
|
2,745
|
(26,246)
|
$
|
2,038,671
|
Net loss
|
|
—
|
(270,401)
|
—
|
—
|
—
|
—
|
—
|
—
|
|
(270,401)
|
Other
comprehensive income
(loss)(ii)
|
|
—
|
22,185
|
—
|
8,718
|
16,430
|
—
|
—
|
—
|
|
47,333
|
Dividends declared
($0.60 per
share)
|
|
—
|
(74,533)
|
—
|
—
|
—
|
—
|
—
|
—
|
|
(74,533)
|
Share-based
compensation
expense
|
|
—
|
—
|
16,945
|
—
|
—
|
—
|
—
|
—
|
|
16,945
|
Modification of
stock
compensation plan
|
|
—
|
—
|
(3,594)
|
—
|
—
|
—
|
—
|
—
|
|
(3,594)
|
Deferred taxes on
share-
based compensation
|
|
—
|
—
|
(2,125)
|
—
|
—
|
—
|
—
|
—
|
|
(2,125)
|
Exercise of stock
options
|
|
5,888
|
—
|
(1,289)
|
—
|
—
|
—
|
—
|
—
|
|
4,599
|
Shares
re-purchased
|
|
(8,333)
|
—
|
(19,231)
|
—
|
—
|
—
|
—
|
—
|
|
(27,564)
|
Shares purchased by
RSU
trust
|
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
(7,500)
|
|
(7,500)
|
Settlement of
share-based
compensation
|
|
—
|
—
|
(15,560)
|
—
|
—
|
—
|
—
|
7,830
|
|
(7,730)
|
Change in obligation
for
repurchase of shares
|
|
8,301
|
(9,181)
|
19,483
|
—
|
—
|
—
|
—
|
—
|
|
18,603
|
Balance at September
30, 2022
|
$
|
852,872
|
880,314
|
—
|
10,755
|
8,989
|
2,945
|
2,745
|
(25,916)
|
$
|
1,732,704
|
(i)
|
Items that are or
may be subsequently reclassified to profit or loss.
|
(ii)
|
Included in other
comprehensive income (loss) is the change in actuarial gains and
losses that will not be reclassified to profit or loss and has been
reclassified to retained earnings.
|
(iii)
|
Restated, refer to
Note 3 of the Consolidated Interim Financial
Statements.
|
Consolidated Interim Statements of Cash Flows
(In thousands of
Canadian dollars)
(Unaudited)
|
Three months ended
Septeber 30,
|
Nine months ended
September 30,
|
2023
|
2022
|
2023
|
2022
|
CASH PROVIDED BY (USED
IN):
|
|
|
|
|
Operating
activities
|
|
|
|
|
|
|
|
|
Net loss
|
$
|
(4,274)
|
$
|
(229,476)
|
$
|
(115,656)
|
$
|
(270,401)
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
|
|
|
|
Change in fair value
of biological assets
|
|
(266)
|
|
31,451
|
|
28,408
|
|
42,104
|
Depreciation and
amortization
|
|
70,204
|
|
57,602
|
|
204,000
|
|
172,032
|
Share-based
compensation
|
|
1,671
|
|
2,727
|
|
7,733
|
|
16,485
|
Deferred income
taxes
|
|
19,851
|
|
1,803
|
|
11,833
|
|
6,615
|
Income tax
current
|
|
(15,823)
|
|
(4,136)
|
|
(30,084)
|
|
(5,621)
|
Interest expense and
other financing costs
|
|
40,467
|
|
14,494
|
|
109,624
|
|
32,996
|
Loss on sale of
long-term assets
|
|
960
|
|
104
|
|
1,935
|
|
1,686
|
Impairment of property
and equipment and
ROU
assets
|
|
2,466
|
|
192,954
|
|
8,996
|
|
209,010
|
Change in fair value
of non-designated
derivatives
|
|
(1,266)
|
|
(6,872)
|
|
(6,792)
|
|
(19,407)
|
Change in net pension
obligation
|
|
1,901
|
|
2,496
|
|
2,232
|
|
6,938
|
Net income taxes
paid
|
|
(4,377)
|
|
(3,371)
|
|
(3,011)
|
|
(29,858)
|
Interest paid, net of
capitalized interest
|
|
(41,183)
|
|
(4,026)
|
|
(108,811)
|
|
(34,414)
|
Change in provision
for restructuring and other
related costs
|
|
(9,401)
|
|
(1,810)
|
|
(28,952)
|
|
1,648
|
Change in derivatives
margin
|
|
1,302
|
|
(2,379)
|
|
(3,984)
|
|
(2,698)
|
Cash settlement of
derivatives
|
|
(2,877)
|
|
—
|
|
5,397
|
|
—
|
Other
|
|
(2,196)
|
|
(2,548)
|
|
(5,892)
|
|
(10,361)
|
Change in non-cash
operating working capital
|
|
58,002
|
|
26,486
|
|
16,895
|
|
(109,756)
|
Cash provided by
operating activities
|
$
|
115,161
|
$
|
75,499
|
$
|
93,871
|
$
|
6,998
|
Investing
activities
|
|
|
|
|
|
|
|
|
Additions to long-term
assets
|
$
|
(51,274)
|
$
|
(78,544)
|
$
|
(156,395)
|
$
|
(257,784)
|
Interest paid and
capitalized
|
|
(1,246)
|
|
(7,019)
|
|
(2,484)
|
|
(16,639)
|
Proceeds from sale of
long-term assets
|
|
10,254
|
|
6
|
|
10,524
|
|
123
|
Purchase of
investments
|
|
(100)
|
|
—
|
|
(200)
|
|
—
|
Cash used in investing
activities
|
$
|
(42,366)
|
$
|
(85,557)
|
$
|
(148,555)
|
$
|
(274,300)
|
Financing
activities
|
|
|
|
|
|
|
|
|
Dividends
paid
|
$
|
(20,660)
|
$
|
(24,759)
|
$
|
(71,912)
|
$
|
(74,533)
|
Net increase in
long-term debt
|
|
647
|
|
84,527
|
|
269,001
|
|
340,474
|
Payment of lease
obligation
|
|
(7,348)
|
|
(8,859)
|
|
(24,728)
|
|
(26,949)
|
Receipt of lease
inducement
|
|
—
|
|
—
|
|
—
|
|
6,847
|
Exercise of stock
options
|
|
2,345
|
|
—
|
|
5,429
|
|
4,599
|
Repurchase of
shares
|
|
—
|
|
(27,564)
|
|
(16,093)
|
|
(27,564)
|
Sale (purchase) of
treasury shares
|
|
—
|
|
—
|
|
9,841
|
|
(7,500)
|
Payment of financing
fees
|
|
(40)
|
|
(59)
|
|
(3,332)
|
|
(3,904)
|
Cash (used in) provided
by financing activities
|
$
|
(25,056)
|
$
|
23,286
|
$
|
168,206
|
$
|
211,470
|
Increase (decrease)
in cash and cash equivalents
|
$
|
47,739
|
$
|
13,228
|
$
|
113,522
|
$
|
(55,832)
|
Cash and cash
equivalents, beginning of period
|
|
156,859
|
|
92,971
|
|
91,076
|
|
162,031
|
Cash and cash
equivalents, end of period
|
$
|
204,598
|
$
|
106,199
|
$
|
204,598
|
$
|
106,199
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-third-quarter-2023-financial-results-301974991.html
SOURCE Maple Leaf Foods Inc.